Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a study of TIN816 in sepsis-associated acute kidney injury
2022-000887-23Phase 2Recruiting
- Sponsor
- Novartis
- Start
- Jul 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in acute kidney failure (AKF) and sepsis comparing TIN816 with Placebo (2 arms). Primary endpoint: Pharmacokinetic profile of TIN816 IV infusion. Started Jul 2022; status: recruiting.
02
Drugs
TIN-816
03
Conditions
acute kidney failure (AKF)sepsis
Beyond the preview
Go deeper on 2022-000887-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000887-23.